RT @MeralElRamahiMD: Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD i
Tweet Content
Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht
Show on Archive Page
On
Display in Search Results
On